Johnson & Johnson is seeking buyers for its sterilization products division, as the health-care conglomerate continues to sell off non-core assets, Bloomberg reported citing people familiar with the matter.
J&J is working with an adviser to solicit bids for the unit, which could fetch as much as $2 billion, the report said. The asset is drawing interest from strategic buyers as well as private equity firms, the people said. Bids are due this week.
No final decision has been made and J&J may choose not to divest the division, the report said.
The advanced sterilization products unit, known as ASP, makes systems and solutions to clean medical tools. Its products, which are sold globally, include the Sterrad system for sterilizing instruments and Cidex OPA solution for disinfecting scopes.
Source: RTT News
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
